Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Cancer Related Cognitive Decline × Trastuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 56 Neoplasm Metastasis 10 Stomach Neoplasms 7 Brain Neoplasms 6 Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Inflammatory Breast Neoplasms 3 HER2-positive Breast Cancer 3 Esophageal Neoplasms 3 Breast Neoplasms, Male 3 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Pancreatic Neoplasms 2 Meningeal Carcinomatosis 2 Lung Neoplasms 2 Central Nervous System Neoplasms 2 Central Nervous System Diseases 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumor, Adult 1 Solid Cancer 1 Sarcoma 1 Recurrence 1 Pathologic Processes 1 Ovarian Neoplasms 1 Nervous System Neoplasms 1 Nervous System Diseases 1 Neoplastic Processes 1 Neoplasms by Site 1

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡